Navigation Links
BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients
Date:4/26/2008

DE (n=1) and 12 percent of

patients receiving adefovir (n=5) experienced a serious adverse event.

-- No deaths were observed in either treatment group.

-- No patients in the BARACLUDE arm and one patient in the adefovir arm

experienced an ALT flare (defined as ALT greater than two times

baseline and greater than 10 times the upper limit of normal).

About the Study

The E.A.R.L.Y. study (ETV-079) is a randomized, open-label, comparative viral kinetics study of antiviral-naive chronic HBeAg-positive patients evaluating antiviral activity as measured by mean reduction in viral load, or levels of hepatitis B virus (HBV DNA) in the blood. HBeAg or e-antigen, is a viral protein associated with hepatitis B infections, and is found in the blood only when there is virus present.

The primary endpoint for the study was mean reduction in HBV DNA levels at week 12. The secondary endpoints included the mean change in viral load from baseline through week 96, the proportion of patients in each treatment group who achieved ALT normalization, HBeAg loss and HBe seroconversion, and safety.

Sixty-nine patients were randomized in the study and of these, 65 completed the first 12 weeks. Patients in this study received either 0.5 mg of BARACLUDE(R) (entecavir) once daily (n=33) or 10 mg of adefovir once daily (n=32) for a minimum of 52 weeks. Patients in the BARACLUDE treatment group had a mean baseline viral load of 10.26 log(10) copies/mL. Patients in the adefovir treatment group had a mean baseline viral load of 9.88 log(10) copies/mL.

According to study protocol, patients who achieved a treatment response at 52 weeks discontinued treatment and entered a follow-up monitoring phase. Three BARACLUDE-treated patients and four adefovir-treated patients met this criterion and entered the follow-up monitoring phase lasting up to 48 weeks. Patients who did not achieve a treatment response at 52 weeks continued on study
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients
2. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
3. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
6. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
9. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
10. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
11. Many Heart Attack Patients Dont Get Best Emergency Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... -- According to a new market research ... Type (Protein & Genetic Biomarkers) Profiling Technology (Proteomics, Genomics, ... - Global Forecast to 2020", published by MarketsandMarkets, The ... Million USD by 2020 at a CAGR of 13.9% ... Browse 191 Tables and 38 F ...
(Date:8/28/2015)... , Aug. 28, 2015 ... has announced the addition of the "12th ... and Production" report to their offering. ... of Biopharmaceutical Manufacturing Capacity and Production is the ... manufacturing organizations, current and projected future capacity and ...
(Date:8/28/2015)... WARRENVILLE, Ill. , Aug. 28, 2015 /PRNewswire/ ... Patterson Companies, Inc. (Nasdaq: PDCO ), is ... the previously announced acquisition of Patterson Medical by ... Medical will retain its name for a transition ... distributor of rehabilitation and sports medicine products.  With ...
Breaking Medicine Technology:Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 2Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 3Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 4Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 512th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 3
... Inc., a biotechnology company developing orally-available antiviral therapeutics, today ... Officer, will present at two upcoming investor conferences in ... on November 16th at 10:30 am at The Pierre ... Conference on November 29 at 11:50 am at The ...
... 2011 PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial ... 2011. (Logo:   http://photos.prnewswire.com/prnh/20111025/LA93174LOGO-c ) ... were $6.0 million, 3% higher than sales of $5.8 ... to increases in sales of the Company,s medical device ...
Cached Medicine Technology:Chimerix to Present at Upcoming Lazard and Piper Jaffray Healthcare Conferences 2Chimerix to Present at Upcoming Lazard and Piper Jaffray Healthcare Conferences 3Pro-Dex, Inc. Announces Fiscal 2012 First Quarter Results 2Pro-Dex, Inc. Announces Fiscal 2012 First Quarter Results 3Pro-Dex, Inc. Announces Fiscal 2012 First Quarter Results 4Pro-Dex, Inc. Announces Fiscal 2012 First Quarter Results 5
(Date:8/30/2015)... CA (PRWEB) , ... August 30, 2015 , ... ... Focused Ultrasound (HIFU) medical devices for the treatment of prostate cancer, has announced ... introduced this summer at the treatment center in Puerto Vallarta, Mexico. , The ...
(Date:8/29/2015)... ... August 30, 2015 , ... Electronic ... 1:30 p.m. – 3:00 p.m. EDT, http://www.fdanews.com/electronicinformedconsent , The simple fact ... handwritten signature. , Clinical trial sites can now use audio, video ...
(Date:8/29/2015)... , ... August 29, 2015 , ... ... insufficient scrotal support and protection against dribbled urine and sweat. "In order to ... Hills, N.Y. , The EASY ACCESS DRYNESS ENHANCED MEN'S UNDERGARMENT provides optimal support ...
(Date:8/29/2015)... ... ... like Toppik , Eau Thermale Avene and Bliss are now available on ... required to qualify for free standard shipping,” said Jennifer Ramirez, the public relations manager. ... the item’s selling price.” , With competitive pricing in the e-commerce market for beauty ...
(Date:8/29/2015)... ... 2015 , ... People who have heart or lung diseases, ... are at higher risk from wildfire smoke especially in Calgary, Alberta.Those with existing ... (arrhythmia or irregular heartbeat) are also sensitive to air pollution. , Tiny ...
Breaking Medicine News(10 mins):Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 3Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 4Health News:Modified Men’s Underwear Promote More Comfort and Hygiene - Designed by InventHelp Client (LGI-1968) 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2
... that pelvic imaging using computed tomography (CT) examinations are ... and eliminating this exam can significantly reduce a patient,s ... the pelvis during CT pulmonary angiography does not improve ... author for this study. He asserts, "Using CT venography ...
... FOR DETERMINING SOURCE OF ACUTE SHORTNESS OF BREATH ... replace standard chest x-ray as the first choice of ... source of acute dyspnea is needed. Italian researchers studied ... strong agreement between the results of chest ultrasonography and ...
... Inhaled Beta-agonists Increase Survival Over Anticholinergics ... agents are commonly prescribed to manage chronic obstructive ... to decrease exacerbations and hospitalizations and improve COPD ... mortality. However, it is not known which therapy ...
... HealthDay Reporter , MONDAY, May 2 (HealthDay News) -- The ... than the brains of normally developing children, and the difference ... The finding is a follow-up to earlier research that found ... of similarly aged normally developing kids, researchers said. ...
... Reporter , MONDAY, May 2 (HealthDay News) -- Kids who ... up getting injured more often, new research suggests. ... pursuit were almost twice as likely to get hurt as ... Neeru Jayanthi, medical director of primary care sports medicine at ...
... May 2 (HealthDay News) -- American workers forced to travel ... study suggests. A team of U.S. researchers found that ... are at higher risk for cardiovascular disease than "light" travelers who ... The team at Columbia University,s Mailman School of Public Health analyzed ...
Cached Medicine News:Health News:Chest journal news briefs, May 2011 issue 2Health News:Embargoed news from Annals of Internal Medicine 2Health News:Embargoed news from Annals of Internal Medicine 3Health News:Brains of Autistic Kids Still Larger at Age 4, 5 2Health News:Brains of Autistic Kids Still Larger at Age 4, 5 3Health News:Kids Specializing in One Sport More Likely to Get Hurt: Study 2Health News:Kids Specializing in One Sport More Likely to Get Hurt: Study 3Health News:Frequent Business Travel Tough on the Heart, Study Finds 2
... 6 is an enzyme immunoassay (EIA) test ... various specific nuclear antigens (SS-A, SS-B, RNP/Sm, ... is used as an aid in the ... connective tissue disease (MCTD), Sjgren's syndrome and ...
The 8500 is an extremely reliable portable pulse oximeter, requiring no periodic maintenance or calibration....
The PalmSAT® 2500 series are small, yet versatile digital pulse oximeters for accurate assessment of blood oxygen saturation and pulse rate. Choose alarm or non-alarm versions for your portable ...
The pocket-size Invacare Digit finger pulse oximeter is a convenient and economical solution to fast, reliable SpO2, pulse rate and pulse strength measurements. Its compact size is ideal for home use...
Medicine Products: